MorphoSys offers $1.7bn for Constellation, but investors see starsShares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to Share XMorphoSys offers $1.7bn for Constellation, but investors see starshttps://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/
Epizyme eyes lucrative use for newly-launched TazverikUS biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the Share XEpizyme eyes lucrative use for newly-launched Tazverikhttps://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/
